Medicovestor’s pancreatic cancer therapy named FDA orphan drug
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ADoBind MC001, an experimental treatment for pancreatic cancer that’s being developed…
Pancreatic cancer
Atebimetinib shows potential for advanced pancreatic cancer: Trial
Most people with advanced pancreatic cancer who received first-line treatment with atebimetinib were alive and free from disease progression six months after starting treatment,…
Elraglusib nearly doubles 1-year survival rates in PDAC clinical trial
Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among people with an advanced form…
Technique for PDAC may help increase effects of chemotherapy
Combining chemotherapy with focused ultrasound and microbubbles is safe and helps deliver chemotherapy drugs more effectively to tumors in people with inoperable pancreatic ductal adenocarcinoma…
PDAC antibody-drug conjugate EBC-129 wins FDA fast track status
U.S. regulators have granted fast track status to the Experimental Drug Development Centre’s (EDDC’s) candidate therapy for pancreatic ductal adenocarcinoma (PDAC), an aggressive form…
Geneseeq’s new blood test may detect early-stage pancreatic cancer
Geneseeq Technology is developing a blood test that uses cell-free DNA (cfDNA) and artificial intelligence (AI) to detect early-stage pancreatic ductal adenocarcinoma — the…
Adding elraglusib seen to improve survival in pancreatic cancer trial
Adding the experimental therapy elraglusib to standard chemotherapy led to statistically significant improvements in survival for people with metastatic pancreatic ductal adenocarcinoma (PDAC), a form…
Adding VCN-01 extends survival in metastatic pancreatic cancer trial
Theriva Biologics’ experimental treatment VCN-01 safely increased survival when used in addition to chemotherapy for people with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC),…
FDA OKs clinical testing of oral treatment for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has given Verastem Oncology the green light to start clinical testing of its oral treatment candidate VS-7375…
MUC5AC protein could predict pancreatic cancer prognosis: Study
Blood levels of the MUC5AC protein could help predict outcomes in people who have surgery for pancreatic ductal adenocarcinoma (PDA), the most common type of…
